Key facts
- This page summarizes David M. Stack's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2023, 17:40.
David M. Stack - 14 Jun 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)
- Reporting relationship
- CEO and Chairman, Director
- Issuer ticker
- PCRX
- Reported as of
- 14 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2023, 17:40:44 UTC
- Prior SEC filing
- 07 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kristen Williams, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David M. Stack filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 16 Jun 2023.
Change
- Previous filing in this sequence was filed on 07 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +32,700
- Change %
- +21%
- Price
- $0.000000
- Shares after
- 186,481
- Date
- 14 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
PCRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 97,273
- Date
- 14 Jun 2023
- Ownership
- By Three Colleens Investment, LLC
- Footnotes
- F2
PCRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,596
- Date
- 14 Jun 2023
- Ownership
- By Stack Schroon Mohawk FLP
- Footnotes
- F2
PCRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 315
- Date
- 14 Jun 2023
- Ownership
- LCK Investment LLC
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PCRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +245,400
- Change %
- Price
- $0.000000
- Shares after
- 245,400
- Date
- 14 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 245,400
- Exercise price
- $38.74
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Footnote F2
Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
Footnote F3
The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.